Eli Lilly and Company (NYSE:LLY) Shares Acquired by Fiduciary Family Office LLC

Key Points

• Fiduciary Family Office LLC significantly increased its investment in Eli Lilly, raising its stake by 2,357% in the first quarter, now holding 2,457 shares valued at approximately $2,029,000.
• Director Jamere Jackson purchased 200 shares at an average price of $639.56, increasing his holdings to 9,402 shares valued at over $6 million.
• Eli Lilly reported a quarterly earnings of $6.31 per share, exceeding estimates and marking a 37.6% increase in revenue year-over-year, with a current market cap of $592.48 billion.

Fiduciary Family Office LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2,357.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,457 shares of the company's stock after purchasing an additional 2,357 shares during the quarter. Eli Lilly and Company comprises about 0.7% of Fiduciary Family Office LLC's portfolio, making the stock its 25th biggest holding. Fiduciary Family Office LLC's holdings in Eli Lilly and Company were worth $2,029,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Taylor Financial Group Inc. lifted its holdings in Eli Lilly and Company by 11.5% in the 1st quarter. Taylor Financial Group Inc. now owns 3,391 shares of the company's stock valued at $2,801,000 after acquiring an additional 350 shares during the last quarter. Manhattan West Asset Management LLC lifted its holdings in Eli Lilly and Company by 24.8% in the 1st quarter. Manhattan West Asset Management LLC now owns 2,127 shares of the company's stock valued at $1,757,000 after acquiring an additional 423 shares during the last quarter. Frank Rimerman Advisors LLC lifted its holdings in Eli Lilly and Company by 2.3% in the 1st quarter. Frank Rimerman Advisors LLC now owns 8,907 shares of the company's stock valued at $7,356,000 after acquiring an additional 202 shares during the last quarter. Koss Olinger Consulting LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at about $388,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eli Lilly and Company by 16.0% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 34,018 shares of the company's stock valued at $28,096,000 after acquiring an additional 4,688 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.13% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $990.89.

Eli Lilly and Company Stock Down 2.5%

LLY opened at $625.15 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $972.53. The stock's fifty day simple moving average is $774.10 and its 200 day simple moving average is $798.80. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market cap of $592.48 billion, a PE ratio of 40.86, a price-to-earnings-growth ratio of 0.91 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 98.25% and a net margin of 25.91%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 1.0%. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.